XORTX Therapeutics Inc.
XRTX Nasdaq
SEC CIK 1729214
Follow XORTX Therapeutics
Weekly email: filings, results
Net income
−CAD 1.7M
−28.6% vs prior year
EPS, diluted
-
Operating cash flow
−CAD 6.1M
−732.3% vs prior year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY21 | −CAD 1.7M |
| FY20 | −CAD 1.3M |
| FY19 | −CAD 629.6K |
| FY18 | - |